• 1
    Lindstrom J, Schelton D, Fujii Y. Myasthenia gravis. Adv Immunol 1988;42:233 84.
  • 2
    Aarli JA, Stefansson K, Marton LSG, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990;82:284 8.
  • 3
    Mygland Å, Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 1992;32:589 91.
  • 4
    Labeit S & Kolmerer B. Titins: giant proteins in charge of muscle ultrastructure and elasticity. Science 1995;270:293 6.
  • 5
    Gautel M, Lakey A, Barlow PD et al Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 1993;43:1581 5.
  • 6
    Skeie GO, Mygland Å, Aarli JA, Gilhus NE. Titin antibodies in patients with late-onset myasthenia gravis: clinical correlations. Autoimmunity 1995;20:99 105.
  • 7
    Williams CL, Hay JE, Huiatt TW, Lennon VA. Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest 1992;66:331 6.
  • 8
    Romagagni S. Human Th1 and Th2 subsets: doubt no more. Immunol Today 1991;12:256 7.
  • 9
    Del Prete GF, De Carli M, Ricci M, Romagagni S. Helper activity for immunoglobulin synthesis of T helper type 1 (Th1) and Th2 human T cell clones: the help of Th1 clones is limited by their cytolytic capacity. J Exp Med 1991;174:583 92.
  • 10
    Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine Leishmaniasis. Evidence for expression of distinct helper T cell subsets. J Exp Med 1989;169:59 72.
  • 11
    Oro AS, Guarino TJ, Driver R, Steinman L, Umetsu DT. Regulation of disease susceptibility: decreased prevalence of IgE-mediated allergic disease in patients with multiple sclerosis. J Allergy Clin Immunol 1996;97:1402 8.
  • 12
    Waisman A, Ruiz PJ, Hirschberg DL et al Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med 1996;2:899 905.
  • 13
    Willcox N. Myasthenia gravis. Curr Opin Immunol 1993;5:910 7.
  • 14
    Hawke S, Matsuo H, Nicolle M, Malcherek G, Melms A, Willcox N. Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Immunol Today 1996;17:307 11.
  • 15
    Skeie GO, Aarli JA, Matre R, Freiburg A, Gilhus NE. Titin antibody positive myasthenia gravis patients have a cellular immune response against the main immunogenic region of titin. Eur J Neurol 1997;4:131 7.
  • 16
    Lefvert AK, Bergstrøm K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978;41:394 403.
  • 17
    LeGrice SFJ & Gruninger-Leitch F. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur J Biochem 1990;187:307 14.
  • 18
    Kabilan L, Anderson G, Lolli F, Ekre HP, Olsson T, Troye-Blomberg M. Detection of intracellular expression and secretion of interferon-γ at the single cell level after activation of human T-cells with tetanus toxoid in vitro. Eur J Immunol 1990;149: 2496 505.
  • 19
    Lanza L, Scudeletti M, Puppo F et al Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol 1996;103:482 90.
  • 20
    Paliogianni F, Ahuja SS, Balow JP et al Novel mechanism for inhibition of human T cells by glucocorticoids. J Immunol 1993; 151:4081 9.
  • 21
    Marx A, Osborn M, Tzartos S et al A striational muscle antigen and myasthenia gravis associated thymomas share an acetylcholine-receptor epitope. Dev Immunol 1992;2:77 84.
  • 22
    Mygland Å, Kuwajima G, Mikoshiba K, Tysnes OB, Aarli JA, Gilhus NE. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol 1995;62:79 83.
  • 23
    Marx A, Wilisch A, Schultz A et al Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Am J Pathol 1996;148:1839 50.
  • 24
    Skeie GO, Freiburg A, Kolmerer B, Labeit S, Aarli JA, Gilhus NE. Titin transcropts in thymoma. J Autoimmun 1997 (in press).
  • 25
    Gilhus NE, Willcox N, Harcourt G et al Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells. J Neuroimmunol 1995;56:65 76.
  • 26
    Kuroda Y, Ken-ichiro O, Neshige R, Shibasaki H. Exacerbation of myasthenia gravis after removal of a thymoma having a membrane phenotype of suppressor T cells. Ann Neurol 1984;15:400 2.
  • 27
    Gilhus NE, Aarli JA, Janzen RW, Otto HF, Fasske E, Matre R. Skeletal muscle antibodies in patients with a thymic tumor but without myasthenia gravis. J Neuroimmunol 1985;8:69 78.
  • 28
    Kuks JBM, Limburg PC, Horst G, Oosterhuis HJGH. Antibodies to skeletal muscle in myasthenia gravis. Part 3. Relation with clinical course and therapy. J Neurol Sci 1993;120:168 73.
  • 29
    Engel WK & McFarlin DE. Muscle lesion in myasthenia gravis. Ann NY Acad Sci 1966;135:68 77.
  • 30
    Hassel B, Gilhus NE, Aarli JA, Skogen OR. Fulminant myasthenia gravis and polymyositis after thymectomy for thymoma. Acta Neurol Scand 1992;85:63 5.
  • 31
    Luebke E, Freiburg A, Skeie GO et al Striational autoantibodies in myasthenia gravis: evidence for titin epitope spreading. J Neuroimmunol 1997 (in press).
  • 32
    Elson CJ, Barker RB, Thomsen SJ, Williams NA. Immunologically ignorant autoreactive T cells, epitope spreading and repertoire limitation. Immunol Today 1995;16:71 6.